Bioequivalence Study of GP-IMP-001 in Healthy Male Volunteers for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis, Psoriatic Arthritis, and Crohn's Disease

The primary objective of this study is to evaluate the **bioequivalence** of GP-IMP-001 in healthy male volunteers under fasting conditions. This is clinically relevant as establishing bioequivalence ensures that the new formulation of the drug provides the same therapeutic effect as the existing approved formulation. The study is intended for the treatment of several conditions, including active **rheumatoid arthritis** in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis when the response to nonsteroidal anti-inflammatory drugs has been inadequate, severe recalcitrant disabling **psoriasis** not adequately responsive to other forms of therapy, severe psoriatic arthritis in adult patients, and mild-to-moderate **Crohn's disease**, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

The clinical trial is designed to evaluate treatments for **active rheumatoid arthritis** in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis, severe psoriatic arthritis, and mild-to-moderate Crohn's disease in adult patients. The study population consists exclusively of male participants, with an age range categorized as adults. The trial does not include vulnerable populations. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed.

The clinical trial is designed as an **open-label**, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study. It involves healthy male volunteers under fasting conditions. The trial aims to evaluate the bioequivalence of GP-IMP-001, which is intended for the treatment of several conditions, including active **rheumatoid arthritis** in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis, severe psoriatic arthritis, and mild-to-moderate **Crohn's disease** in adult patients who are refractory or intolerant to thiopurines. The trial is categorized as a Phase 2 study.

The trial is expected to commence recruitment on September 25, 2025, and is estimated to conclude by November 8, 2025. Participants will be involved in the study for a duration that includes an initial screening visit, two treatment periods, and a final end-of-study visit. The screening visit will determine eligibility based on predefined inclusion and exclusion criteria. During the treatment periods, participants will receive the investigational product under controlled conditions, with each period separated by a washout phase to ensure no carryover effects. The end-of-study visit will assess the overall health and any adverse effects experienced by the participants.

Participants are expected to remain in the study for the entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions, non-compliance with study protocols, or withdrawal of consent. The study's design ensures that all procedures are conducted in accordance with ethical standards and regulatory requirements, providing a robust framework for evaluating the bioequivalence of the investigational product.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, indicating its focus on evaluating the efficacy and side effects of the intervention. The trial is scheduled to commence recruitment on September 25, 2025, with an estimated completion date of November 8, 2025. The specific parameters or endpoints for efficacy assessment, as well as the methods and tools for measurement, are not detailed in the available data. The trial will proceed according to the established protocol for Phase 2 studies, which typically involves a focus on determining the optimal dose and assessing the intervention's efficacy in a larger group of participants than in Phase 1 trials.